Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2025-08-25 AGM Information
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
Biocartis Group - AGM 2025 - Written Questions and Responses (NL) - Final (25 August 2025).pdf
AGM Information Classification · 100% confidence The document is a formal 'Questions and Answers' (Q&A) document prepared by the Board of Directors of Biocartis Group NV in response to shareholder inquiries regarding the company's financial status, the delay of the Annual General Meeting (AGM), and the liquidation process. While it addresses topics related to the AGM, it is a supplementary document providing management's explanations and responses to specific shareholder queries, which is a standard component of AGM information materials provided to shareholders to facilitate the meeting process.
2025-08-25 Dutch
Biocartis Group - AGM 2025 - Minutes (ENG) (25 August 2025).pdf
AGM Information Classification · 100% confidence The document is titled 'MINUTES OF THE ORDINARY GENERAL SHAREHOLDERS' MEETING' and details the proceedings, agenda items, and resolutions passed during the meeting held on 25 August 2025. It covers topics such as the approval of financial statements, discharge of directors, remuneration reports, and the appointment of auditors. This content is characteristic of AGM-related documentation, specifically the minutes recording the outcomes of the meeting.
2025-08-25 English
Biocartis Group - AGM 2025 - Minutes (NL) (25 August 2025).pdf
AGM Information Classification · 100% confidence The document is titled 'NOTULEN VAN DE GEWONE ALGEMENE AANDEELHOUDERSVERGADERING' (Minutes of the Ordinary General Meeting of Shareholders) for Biocartis Group NV. It details the proceedings, agenda items, voting proposals, and resolutions passed during the meeting held on August 25, 2025. Since it contains the official record of the meeting's proceedings and voting outcomes, it is classified as AGM Information.
2025-08-25 Dutch
Auditor Report - Consolidated Financial Statements FY 2023.pdf
Audit Report / Information Classification · 100% confidence The document is explicitly titled 'Statutory auditor's report to the shareholders' meeting' and contains the audit opinion, basis for opinion, and key audit matters regarding the consolidated financial statements of Biocartis Group NV for the year ended 31 December 2023. It is a standalone audit report provided by Deloitte, distinct from the full Annual Report (10-K). Therefore, it falls under the Audit Report category. FY 2023
2025-07-25 English
Annual report 2023.pdf
Annual Report Classification · 100% confidence The document is titled '2023' and explicitly identifies itself as an 'annual report' for the period starting 1 January 2023 to 31 December 2023. It contains detailed sections on the company's business, risk factors, corporate governance, and financial status (including the decision to liquidate). It is a comprehensive report covering the full fiscal year, fitting the definition of an Annual Report (10-K). FY 2023
2025-07-25 English
Board report (7-228).pdf
Legal Proceedings Report Classification · 100% confidence The document is a 'Special Report of the Board of Directors' prepared in accordance with specific articles of the Belgian Companies and Associations Code (7:228 and 7:229). It details the company's financial distress, the loss of net assets, and the board's proposal for voluntary dissolution and liquidation. It includes a statement of assets and liabilities as an annex. This document is a formal governance and management report regarding the company's legal and financial status, which fits best under the 'Management Reports' (MDA) category as it provides management's detailed explanation of the company's situation and outlook.
2025-07-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.